Karyopharm Therapeutics Inc. KPTI
Price alert —
Sign in to get a one-time email the moment KPTI crosses your price. Free accounts included.
Sign in / create a free accountPrice chart
Loading…
Latest bar · KPTI
Momentum reads · latest daily barGreen means room to run, red means stretched — the reads re-read live as you switch the chart's timeframe. MFI(14) is a volume-weighted money-flow read: above 80 = overbought, below 20 = oversold.
Financial overlay · last 12 quarters
The story behind the price: three years of quarterly results laid over the chart, so you can see whether the stock has been following the business — or running ahead of it.
| Quarter | Revenue | Net income | Op income | FCF | Net margin | Op margin |
|---|---|---|---|---|---|---|
| 2026-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -63.9% | -76.3% |
| 2025-12-31 | $0.0B | $-0.1B | $-0.0B | $-0.0B | -299.9% | -52.4% |
| 2025-09-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -75.2% | -34.6% |
| 2025-06-30 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -98.2% | -64.3% |
| 2025-03-31 | $0.0B | $-0.0B | $-0.0B | $-0.0B | -78.2% | -110.8% |
| 2024-12-31 | $nanB | $nanB | $nanB | $nanB | nan% | nan% |
Tip: toggle P/E, FCF, ROE, Gross margin and more on the chart above — every overlay is free.
Compare KPTI vs peers
Line KPTI up against up to 4 peers (5 tickers total) across ~30 metrics and get one weighted 0-100 verdict — best in green, worst in red. Peers also overlay on the chart above as rebased % lines, or flip the chart to the 2×2 grid for side-by-side mini charts.
AVGO
AVGO
$370.83
-0.97%
Earnings replay · last 20 reports
How this stock actually behaves on report day: each past earnings print with the beat-or-miss and the next-day move — a track record for handicapping the next one.
| Date | EPS actual | EPS est | Surprise | Next-day |
|---|---|---|---|---|
| 2026-05-14 | -1.24 | -1.44 | +14.1% | -13.8% |
| 2026-02-12 | -2.23 | -2.00 | -11.3% | -4.0% |
| 2025-11-03 | -3.82 | -3.25 | -17.5% | -6.9% |
| 2025-08-11 | -4.07 | -3.91 | -4.0% | +6.6% |
| 2025-05-12 | -2.77 | -3.09 | +10.3% | -20.0% |
| 2025-02-19 | -3.60 | -4.03 | +10.7% | +1.7% |
| 2024-11-05 | -3.90 | -3.92 | +0.6% | +4.8% |
| 2024-08-06 | -4.34 | -4.47 | +2.8% | -3.5% |
| 2024-05-08 | -4.80 | -4.94 | +2.9% | +4.9% |
| 2024-02-29 | -5.40 | -4.65 | -16.2% | +2.2% |
| 2023-11-02 | -4.50 | -4.29 | -5.0% | +16.9% |
| 2023-08-02 | -4.35 | -5.04 | +13.8% | +1.1% |
| 2023-05-04 | -4.50 | -5.23 | +13.9% | -2.2% |
| 2023-02-15 | -6.45 | -5.38 | -19.9% | -1.9% |
| 2022-11-03 | -6.75 | -8.02 | +15.9% | +4.4% |
| 2022-08-04 | -9.30 | -9.55 | +2.6% | +3.3% |
| 2022-05-05 | -7.95 | -9.24 | +14.0% | -9.8% |
| 2022-02-08 | 6.90 | -6.37 | +208.4% | +10.6% |
| 2021-11-03 | -10.35 | -10.27 | -0.8% | +0.4% |
| 2021-08-05 | -10.65 | -10.97 | +2.9% | -6.9% |
Earnings markers are overlaid on the daily price chart above. Click a ▲ marker for that day's move.
Peer comparison · Healthcare
Context check: the same key numbers for the closest Healthcare names side by side, so you can tell whether this stock is the standout or just moving with its group.
| Ticker ⇅ | Mkt cap ⇅ | P/E ⇅ | Fwd P/E ⇅ | P/S ⇅ | EV/EBITDA ⇅ | P/B ⇅ | Gross M ⇅ | Rev gr ⇅ | EPS gr ⇅ | FCF yld ⇅ |
|---|---|---|---|---|---|---|---|---|---|---|
| KPTI ★ | — | — | — | — | — | — | — | 16.8% | — | — |
| LLY | $1,051B | 41.5 | 26.3 | 14.6 | 30.1 | 33.8 | 82.8% | 55.5% | 169.9% | 0.87% |
| UNH | $387B | 31.8 | 19.2 | 0.9 | 20.2 | 4.0 | 18.8% | 2.0% | 0.7% | 4.57% |
| JNJ | $609B | 29.0 | 19.7 | 6.2 | 18.4 | 7.5 | 68.1% | 6.6% | -1.0% | — |
| MRK | $315B | 36.0 | 13.2 | 4.8 | 12.1 | 6.9 | 76.7% | 4.9% | — | 4.46% |
| ABBV | $450B | 124.8 | 15.6 | 7.2 | 17.2 | -67.6 | 72.0% | 12.4% | -46.2% | 4.63% |
| PFE | $143B | 19.1 | 8.8 | 2.3 | 7.6 | 1.6 | 74.8% | 5.4% | -10.1% | 8.67% |
| TMO | $198B | 29.8 | 19.5 | 4.4 | 21.1 | 3.8 | 40.9% | 6.2% | 11.3% | 2.79% |
Auto-seeded from sector. Click any ticker to switch.
Ownership
Who holds the stock and what they've been doing lately — big funds on the left, executives' own buys and sells on the right. Insider buying is the rarer, louder signal.
Top institutional holders
Top-10 concentration: 50.73%
| Holder | Shares | % out |
|---|---|---|
| Commodore Capital Lp | 1,950,000 | 8.60% |
| RA Capital Management, L.P. | 1,917,354 | 8.46% |
| Adage Capital Partners GP L.L.C. | 1,806,322 | 7.97% |
| T. Rowe Price Investment Management, | 1,542,090 | 6.80% |
| Goldman Sachs Group Inc | 947,579 | 4.18% |
| Catalio Capital Management, LP | 897,709 | 3.96% |
| Vanguard Capital Management LLC | 739,745 | 3.26% |
| Ikarian Capital, LLC | 733,435 | 3.24% |
| Affinity Asset Advisors, Llc | 500,000 | 2.21% |
| Avidity Partners Management, LP | 463,741 | 2.05% |
Insider activity · 90d
9 buys / 6 sells · ratio 1.5 · Finnhub
- Su Zhen BUY 15,508
- Oliger Christy J. BUY 15,508
- Schor Chen BUY 15,508
- Greene Barry E BUY 16,415
- PAKIANATHAN DEEPIKA BUY 15,508
- BOHLIN GAREN G BUY 18,517
- Poulton Stuart SELL 94,821 @ $9.50
- Rangwala Reshma SELL 56,829 @ $9.50
- Cheng Sohanya Roshan SELL 107,940 @ $9.50
- Abate Kristin SELL 23,801 @ $9.50
Analyst estimates
FinnhubWhat Wall Street expects next: the consensus forecasts for the coming quarters. The market usually reacts to results versus these numbers, not the raw results themselves.
SEC filings
The company's own paperwork, straight from the regulator — annual and quarterly reports, big announcements and insider trades. The primary source behind every headline.
| Form | Filed | Description | Action |
|---|---|---|---|
| 8-K | 2026-07-17 | 8-K | view · |
| 8-K | 2026-05-28 | 8-K | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-26 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 4 | 2026-05-15 | 4 | view · |
| 10-Q | 2026-05-14 | 10-Q | view · |
| 8-K | 2026-05-14 | 8-K | view · |
| 4 | 2026-04-22 | 4 | view · |
| DEF 14A | 2026-04-13 | DEF 14A | view · |
| 8-K | 2026-03-27 | 8-K | view · |
| 8-K | 2026-03-24 | 8-K | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 4 | 2026-03-03 | 4 | view · |
| 8-K | 2026-03-03 | 8-K | view · |
| 8-K | 2026-02-19 | 8-K | view · |
| 4 | 2026-02-19 | 4 | view · |
| 10-K | 2026-02-13 | 10-K | view · |
| 8-K | 2026-02-12 | 8-K | view · |
| 4 | 2026-02-09 | 4 | view · |
| 4 | 2026-02-04 | 4 | view · |
| 4 | 2026-02-03 | 4 | view · |
| 4 | 2026-02-03 | 4 | view · |
| 4 | 2026-02-03 | 4 | view · |
| 4 | 2026-02-03 | 4 | view · |
| 4 | 2026-02-03 | 4 | view · |
| 4 | 2026-01-29 | 4 | view · |
| 4 | 2026-01-22 | 4 | view · |
| 8-K | 2026-01-12 | 8-K | view · |
| DEF 14A | 2026-01-09 | DEF 14A | view · |
| 10-Q | 2025-11-03 | 10-Q | view · |
| 8-K | 2025-11-03 | 8-K | view · |
| 4 | 2025-10-16 | 4 | view · |
| 4 | 2025-10-16 | 4 | view · |
| 4 | 2025-10-16 | 4 | view · |
| 4 | 2025-10-16 | 4 | view · |
| 4 | 2025-10-16 | 4 | view · |
| 4 | 2025-10-16 | 4 | view · |
| 8-K | 2025-10-14 | 8-K | view · |
| 8-K | 2025-10-08 | 8-K | view · |
| 4 | 2025-10-03 | 4 | view · |
| 4 | 2025-09-16 | 4 | view · |
| 4 | 2025-09-16 | 4 | view · |
| 4 | 2025-09-16 | 4 | view · |
| 4 | 2025-09-16 | 4 | view · |
| 4 | 2025-09-16 | 4 | view · |
| 4 | 2025-09-16 | 4 | view · |
| 8-K | 2025-09-11 | 8-K | view · |
About KPTI
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene …
Options picks · KPTI
ITM + OTM ideas from the latest scanLoading…
Congress trades · KPTI
STOCK Act disclosuresLoading…
SEC filings & insiders · KPTI
EDGAR · liveLoading…
Holders · KPTI
Institutions & insider activityLoading…